Programmed cell death ligand 1 (PD-L1), as well as tumor mutational burden (TMB), are commonly used as indicators for the evaluation of the efficacy of immunotherapy and identify populations that are likely to benefit from immunotherapy (19). Here, CD274 is linked to neoplasm.